Related Experiment Videos
Monoclonal antibodies with high affinity for spiroperidol
R R Luedtke1, M Korner, K A Neve
1Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia 19104-6084.
Journal of Neurochemistry
|April 1, 1988
Summary
Researchers developed monoclonal antibodies targeting spiroperidol (SPD) and related compounds. These antibodies show high affinity binding, aiding in the characterization of dopamine D2 receptors and potential drug interactions.
Area of Science:
- Immunology
- Neuropharmacology
- Biochemistry
Background:
- Spiperidol (SPD) is a key compound for studying dopamine D2 receptors.
- Developing specific antibodies is crucial for understanding drug-receptor interactions.
Purpose of the Study:
- To generate and characterize a diverse panel of monoclonal antibodies against spiroperidol (SPD).
- To investigate the binding characteristics and selectivity of these antibodies for dopamine D2 receptor ligands.
Main Methods:
- Immunization of BALB/c mice with SPD-related haptens coupled to a protein carrier.
- Hybridoma selection based on high-affinity binding to [3H]SPD.
- Inhibition assays using various dopamine receptor ligands to characterize antibody binding sites.
Main Results:
- Generated antibodies with high affinity for SPD, ranging from 0.2 to over 100 nM dissociation constants.
- Identified 12 distinct classes of antibody binding sites based on ligand inhibition patterns.
- Some antibodies demonstrated cross-reactivity with domperidone, a non-butyrophenone D2 antagonist.
Conclusions:
- The developed monoclonal antibodies are valuable tools for probing the spiroperidol binding site on dopamine D2 receptors.
- Antibody characterization reveals insights into the structural requirements for D2 receptor ligand binding.
- This work contributes to the development of selective antagonists and understanding of dopaminergic pathways.